# Suneva Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suneva-medical

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.sunevamedical.com
- Total disclosed funding: $45M
- Latest round: Series D (Jun 14, 2016)
- Investors on record: 4

## About

Suneva Medical, Inc. is a US-based medical aesthetics company specializing in innovative regenerative solutions designed to enhance aesthetic outcomes across various applications.Founded in 2009 and headquartered in San Diego, US, Suneva Medical, Inc. develops advanced aesthetic medical products. The company has raised a total of USD 15.00 mn through 13 deals, with its most recent funding of USD 1.00 mn in VENTURE DEBT completed on January 3, 2022. Pat Altavilla serves as CEO, bringing extensive experience in the industry.Suneva Medical offers a comprehensive array of aesthetic products including the Structural Adipose Filler, an innovative solution for body aesthetics, and an FDA-cleared 5-year filler for long-lasting results. Their product line also features the first silicone gel breast implants with high safety standards and a Universal no-touch implant delivery device. Other products include the Silhouette Instalift and Amplifine PRP platform, catering to the needs of healthcare professionals and aesthetic practices across the US and select international markets.Suneva Medical generates revenue through direct sales to medical practitioners and healthcare facilities, focusing on a B2B model. Their flagship products, such as the Bellafill® biostimulatory filler and Viality Enhanced Viability Fat Transfer system, are supplied to clinics and hospitals through bulk orders and ongoing partnerships, effectively supporting their revenue streams.With the funding secured in January 2022, Suneva Medical plans to further expand its product offerings and penetrate new markets. Upcoming releases include innovative products designed for both surgical and non-surgical aesthetic applications, aiming for launch within the next year. The company is targeting expansion into additional international markets, enhancing its global footprint by 2023.

## Funding rounds

- Series D, Jun 14, 2016, $25M — Essex Woodlands, Healthcare Royalty Partners, Polaris Partners, Almirall
- Series B, Jan 9, 2014, $20M — Healthcare Royalty Partners, Polaris Partners

## Investors

- Healthcare Royalty Partners (https://capitalatlas.ai/funds/healthcare-royalty-partners) — Series B, Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series D
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series D
- Almirall — Series D